StreetInsider.com News Articles

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

Mon, 10 Aug 2026 09:05:00 -0400

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

Mon, 10 Aug 2026 09:05:00 -0400

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

Mon, 10 Aug 2026 09:05:00 -0400

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

Mon, 10 Aug 2026 09:05:00 -0400

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord

Mon, 10 Aug 2026 07:29:15 -0400

(Updated - August 10, 2026 7:29 AM EDT)

Canaccord analyst Whitney Ijem raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $114.00 (from $111.00) while maintaining a Buy rating.

The analyst commented: "BMRN’s 2Q26 earnings report (slides here) ~in line with revenue growth driven by the addition of GALAFOLD and POMBILITI + OPFOLDA from the recently closed Amicus acquisition. The co raised FY26 guidance for total revenue, Voxzogo revenue, and non-GAAP diluted EPS. Mgmt also provided more detail on Amicus cost synergies and laid out plans to grow GALAFOLD and POMBILITI + OPFOLDA (details below). On Voxzogo, mgmt noted that,

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord

Mon, 10 Aug 2026 07:29:15 -0400

(Updated - August 10, 2026 7:29 AM EDT)

Canaccord analyst Whitney Ijem raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $114.00 (from $111.00) while maintaining a Buy rating.

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $70 at Stifel

Fri, 07 Aug 2026 10:22:39 -0400

Stifel analyst Paul Matteis raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $70.00 (from $68.00) while maintaining a Hold rating.

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $97 at Oppenheimer

Fri, 07 Aug 2026 06:17:25 -0400

Oppenheimer analyst Leland Gershell raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $97.00 (from $95.00) while maintaining a Outperform rating.

The analyst comments "BMRN reported 2Q revenue of $990M (+20% Y/Y) and $1.20 non-GAAP EPS, and raised full-year Voxzogo/total revenue and EPS guidance. The quarter also provided the first detailed look at the Amicus integration, including $220M of expected non-GAAP cost synergies by 2028, peak sales targets of $1.4B for Galafold and $1.2B for Pombiliti+Opfolda, and an accelerated deleveraging timeline. Voxzogo demand remained healthy despite Yuviwel's launch, and hypochondroplasia sNDA has been submitted to FDA following positive Phase

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $97 at Oppenheimer

Fri, 07 Aug 2026 06:17:25 -0400

Oppenheimer analyst Leland Gershell raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $97.00 (from $95.00) while maintaining a Outperform rating.

Form S-8 BIOMARIN PHARMACEUTICAL

Thu, 06 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260806/26885672.html

Form S-8 BIOMARIN PHARMACEUTICAL

Thu, 06 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260806/26885672.html

BioMarin Pharma (BMRN) Tops Q2 EPS by 25c

Thu, 06 Aug 2026 17:13:31 -0400

BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $1.20, $0.25 better than the analyst estimate of $0.95. Revenue for the quarter came in at $990 million versus the consensus estimate of $939.37 million.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

Form 10-Q BIOMARIN PHARMACEUTICAL For: Jun 30

Thu, 06 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26884210.html

Form 10-Q BIOMARIN PHARMACEUTICAL For: Jun 30

Thu, 06 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26884210.html

Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 06

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883708.html

Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 06

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883708.html

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Thu, 06 Aug 2026 16:03:00 -0400

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million

Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO^®, and Non-GAAP Diluted Earnings Per Share (EPS)

Addition of GALAFOLD^® and POMBILITI^® + OPFOLDA^®, with Cost Synergies, Expected to Accelerate Revenue Growth, Non-GAAP Diluted EPS Accretion, Non-GAAP Operating Margin Expansion, and Operating Cash Flow through the Mid-2030s

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., Aug. 6, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30,

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Thu, 06 Aug 2026 16:03:00 -0400

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million

Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO^®, and Non-GAAP Diluted Earnings Per Share (EPS)

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., Aug. 6, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30,

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Thu, 06 Aug 2026 16:03:00 -0400

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million

Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO^®, and Non-GAAP Diluted Earnings Per Share (EPS)

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., Aug. 6, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30,

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Thu, 06 Aug 2026 16:03:00 -0400

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million

Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO^®, and Non-GAAP Diluted Earnings Per Share (EPS)

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., Aug. 6, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30,

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Thu, 06 Aug 2026 16:03:00 -0400

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million

Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO^®, and Non-GAAP Diluted Earnings Per Share (EPS)

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., Aug. 6, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30,

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Thu, 06 Aug 2026 16:03:00 -0400

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million

Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO^®, and Non-GAAP Diluted Earnings Per Share (EPS)

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., Aug. 6, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30,

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Thu, 06 Aug 2026 16:03:00 -0400

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million

Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO^®, and Non-GAAP Diluted Earnings Per Share (EPS)

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., Aug. 6, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30,

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Thu, 06 Aug 2026 16:03:00 -0400

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million

Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO^®, and Non-GAAP Diluted Earnings Per Share (EPS)

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., Aug. 6, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30,

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Thu, 06 Aug 2026 16:03:00 -0400

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million

Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO^®, and Non-GAAP Diluted Earnings Per Share (EPS)

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., Aug. 6, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30,